Key facts
- Catch Bio’s last known valuation is $60.0M (Mar 2025).
- It has raised $40.8M; the latest was Early Stage VC ($750K) in Mar 2026.
- Notable investors include Spacestation (UK), DML Group, Grt Sht Ventures, Hannah Grey Ventures, Wild Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Catch Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Catch Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Catch Bio
Developer of a preventive health platform designed to help people understand and lower their risk of cancer. The company offers risk assessments based on validated health factors, biomarker analysis, and personalized action plans, enabling individuals concerned about long-term cancer risk to make informed lifestyle and screening decisions.
- Sector
- Healthcare
- HQ
- Lewes, DE, United States
- Founded
- 2023
- Website
- catchbio.com/
- Ownership
- Privately Held (backing)
Catch Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Catch Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Catch Bio in its N-PORT filings yet. We sweep new filings monthly.